Synklino
About:
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Website: https://synklino.com/
Top Investors: Maj Invest Equity, Vaekstfonden, BioInnovation Institute, EIR Ventures, PKA
Description:
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
Total Funding Amount:
232M DKK
Headquarters Location:
Lyngby, Hovedstaden, Denmark
Founded Date:
2017-01-01
Contact Email:
tnk(AT)synklino.com
Founders:
Thomas Kledal
Number of Employees:
1-10
Last Funding Date:
2022-06-08
IPO Status:
Private
Industries:
© 2025 bioDAO.ai